'The Facts'

Telix Pharmaceuticals (ASX:TLX) has taken another step in expanding its neuro-oncology portfolio, announcing the submission of a European marketing authorisation application for its brain cancer imaging candidate TLX101-Px.

Australian pharmaceutical manufacturer IDT says it is beginning to show tangible signs of recovery after a period of leadership change and financial pressure, reporting improved earnings and renewed operational momentum in the first half of the financial year 2026.

Nyrada (ASX:NYR) has confirmed growing clinical momentum, strengthening finances, and expanding scientific validation for its lead candidate, Xolatryp, as the company positions itself for its next phase of development.

The program is funded by Novo Nordisk through its 'Cities for Better Health' initiative, which partners with cities worldwide to tackle chronic disease through prevention and healthier urban living.

CSL has taken another step in its push to expand its portfolio of innovative therapies, announcing a new licensing agreement with Eli Lilly that could broaden the future reach of its monoclonal antibody candidate, clazakizumab.

People in New Zealand living with chronic lymphocytic leukaemia may soon gain funded access to modern targeted therapies under a new proposal from Pharmac.

Percheron Therapeutics (ASX:PER) is positioning itself as a small but strategically focused biotechnology company seeking to carve out a role in the rapidly expanding immuno-oncology market.

As global health leaders gather in Sydney for this week’s Global Antimicrobial Resistance Summit, one message is clear. The world is running out of time to address the growing threat of antibiotic-resistant infections.

Recently elected Opposition Leader Angus Taylor has confirmed that South Australian senator Anne Ruston will remain responsible for the health and aged care portfolio, signalling continuity in the Coalition’s approach to two of the country's most politically sensitive policy areas.

The proposal, led by Advanced Pharmacy Australia, argues that medicine shortages are no longer isolated incidents but a persistent structural challenge for the health system.

Australia’s PBS decision-making framework was built to make difficult decisions fairly, in theory. The reality is that decisions made ethically consistent within this framework can produce outcomes that are intrinsically unethical because of their intolerable human impact. At that point, where the consequence is suffering or death, they become immoral.

The PBS has come under renewed scrutiny in Washington after the U.S. pharmaceutical industry used a submission to call for Australia’s inclusion on its Priority Watch List.